Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.02.004
Abstract: The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most trials reporting changes in bone mineral density as a surrogate. The AZURE trial (ISRCTN79831382) evaluated the impact of adjuvant zoledronic acid… read more here.
Keywords: zoledronic acid; fracture; adjuvant zoledronic; breast cancer ... See more keywords